Ingevity Corp (NGVT) Q3 2025 10-Q Quarterly Report

Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Chemicals & Allied ProductsSEC EDGAR

Ingevity Corp (NGVT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Ingevity Corp Q3 2025 10-Q Analysis

Risk Factors

  • Newly added trade policy risk from new U.S. tariffs and Chinese retaliatory measures lowering margins on products sold into China
  • Materially updated operational risk of facility disruptions, including labor strikes with recent CBA expirations and renewals through mid-2025
+3 more insights

Ingevity Corp Q3 2025 Quarterly Financials
XBRL

Revenue

$263M

-30.1% YoY -27.9% QoQ

Net Income

$44M

+140.6% YoY +129.7% QoQ

Gross Margin

46.5%

+1200bp YoY +870bp QoQ

Net Margin

16.5%

+4496bp YoY +5664bp QoQ

ROE

31.5%

Total Assets

$1.8B

EPS (Diluted)

$1.19

+140.3% YoY +129.6% QoQ

Operating Cash Flow

$130M

+178.9% YoY +64.2% QoQ

Source: XBRL data from Ingevity Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Ingevity Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.